{"organizations": [], "uuid": "a6ff0cf3fdbd110e6b6d44850b56a3dbe11bf879", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/2", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/01/26/pr-newswire-perrigo-announces-tentative-fda-approval-for-the-generic-version-of-onextona-gel.html", "country": "US", "domain_rank": 767, "title": "Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 1.0, "site_type": "news", "published": "2018-01-26T20:53:00.000+02:00", "replies_count": 0, "uuid": "a6ff0cf3fdbd110e6b6d44850b56a3dbe11bf879"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/01/26/pr-newswire-perrigo-announces-tentative-fda-approval-for-the-generic-version-of-onextona-gel.html", "ord_in_thread": 0, "title": "Perrigo Announces Tentative FDA Approval For The Generic Version Of Onexton® Gel", "locations": [], "entities": {"persons": [{"name": "john wesolowski", "sentiment": "none"}], "locations": [{"name": "dublin", "sentiment": "none"}], "organizations": [{"name": "perrigo", "sentiment": "negative"}, {"name": "tase", "sentiment": "negative"}, {"name": "perrigo company plc", "sentiment": "negative"}, {"name": "nyse", "sentiment": "negative"}, {"name": "dow pharmaceutical sciences, inc.", "sentiment": "none"}, {"name": "perrigo perrigo company plc", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "valeant pharmaceuticals north america llc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "DUBLIN, Jan. 26, 2018 /PRNewswire/ -- Perrigo Company plc (NYSE; TASE: PRGO) today announced it has received tentative approval from the U.S. Food and Drug Administration for the generic version of Onexton ® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%). Perrigo previously settled litigation with Valeant Pharmaceuticals North America LLC and Dow Pharmaceutical Sciences, Inc. for this product.\nOnexton ® Gel (clindamycin phosphate 1.2% and benzoyl peroxide 3.75%) is a prescription medicine indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Branded market sales for the last 12 months were approximately $115 million.\nPerrigo Executive Vice President and President Rx Pharmaceuticals John Wesolowski stated, \"This tentative approval is another example of making long-term investments in our extended topicals strategy. The Rx team continues to invest in bringing important products to market that provide savings to patients and healthcare systems.\"\nAbout Perrigo\nPerrigo Company plc, a leading global healthcare company, delivers value to its customers and consumers by providing Quality Affordable Healthcare Products ® . Founded in 1887 as a packager of home remedies, Perrigo has built a unique business model that is best described as the convergence of a fast-moving consumer goods company, a high-quality pharmaceutical manufacturing organization and a world-class supply chain network. Perrigo is one of the world's largest manufacturers of over-the-counter (\"OTC\") healthcare products and suppliers of infant formulas for the store brand market. The Company also is a leading provider of branded OTC products throughout Europe and the U.S., as well as a leading producer of \"extended topical\" prescription drugs. Perrigo, headquartered in Ireland, sells its products primarily in North America and Europe, as well as in other markets, including Australia, Israel and China. Visit Perrigo online at ( http://www.perrigo.com ).\nForward-Looking Statements\nCertain statements in this press release are \"forward-looking statements.\" These statements relate to future events or the Company's future financial performance and involve known and unknown risks, uncertainties and other factors that may cause the actual results, levels of activity, performance or achievements of the Company or its industry to be materially different from those expressed or implied by any forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as \"may,\" \"will,\" \"could,\" \"would,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"intend,\" \"believe,\" \"estimate,\" \"predict,\" \"potential\" or the negative of those terms or other comparable terminology. The Company has based these forward-looking statements on its current expectations, assumptions, estimates and projections. While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control, including: the timing, amount and cost of any share repurchases; future impairment charges; the success of management transition; customer acceptance of new products; competition from other industry participants, some of whom have greater marketing resources or larger market shares in certain product categories than the Company does; pricing pressures from customers and consumers; potential third-party claims and litigation, including litigation relating to the Company's restatement of previously-filed financial information; potential impacts of ongoing or future government investigations and regulatory initiatives; resolution of uncertain tax positions; the impact of U.S. tax reform legislation and healthcare policy; general economic conditions; fluctuations in currency exchange rates and interest rates; the consummation of announced acquisitions or dispositions, and the Company's ability to realize the desired benefits thereof; and the Company's ability to execute and achieve the desired benefits of announced cost-reduction efforts and other initiatives. In addition, the Company may be unable to remediate one or more previously identified material weaknesses in its internal control over financial reporting. Furthermore, the Company may incur additional tax liabilities in respect of 2016 and prior years or be found to have breached certain provisions of Irish company law in connection with the Company's restatement of previously filed financial statements, which may result in additional expenses and penalties. These and other important factors, including those discussed under \"Risk Factors\" in the Company's Form 10-K for the year ended December 31, 2016, as well as the Company's subsequent filings with the United States Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\nView original content with multimedia: http://www.prnewswire.com/news-releases/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-onexton-gel-300588900.html\nSOURCE Perrigo Company plc", "external_links": ["http://www.perrigo.com/", "http://www.prnewswire.com/news-releases/perrigo-announces-tentative-fda-approval-for-the-generic-version-of-onexton-gel-300588900.html"], "published": "2018-01-26T20:53:00.000+02:00", "crawled": "2018-01-26T23:45:28.000+02:00", "highlightTitle": ""}